Please login to the form below

Not currently logged in
Email:
Password:

Imbruvica

This page shows the latest Imbruvica news and features for those working in and with pharma, biotech and healthcare.

AbbVie, Roche get FDA OK for broader use of Venclexta

AbbVie, Roche get FDA OK for broader use of Venclexta

A marketing application in AML is due shortly. They are also investigating its use in combination with AbbVie’s flagship cancer drug Imbruvica (ibrutinib), a BTK inhibitor also approved for CLL

Latest news

More from news
Approximately 27 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Pharma deals in March 2015 Pharma deals in March 2015

    Imbruvica is co-commercialised by J&J with Pharmacyclics on a global profit share arrangement under a deal agreed in December 2011. ... At that time Imbruvica was in phase 2 and J&J paid $150m upfront and up to $825m in milestones.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica.

  • Pharma deals during October 2014 Pharma deals during October 2014

    Imbruvica was one of the first products to gain approval via the breakthrough designation pathway and has European approval for use in mantle cell leukaemia and chronic lymphocytic leukaemia. ... Originally the subject of a deal signed in December 2011

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics